Search results
Added:
1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further…
View more
Added:
1 year ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more
Added:
1 year ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of…
View more
Staging of Heart Failure with Preserved Ejection Fraction
Added:
1 year ago
Expert Opinion
Added:
1 year ago
HFSA 24 - Dr Akshay Desai (Brigham and Women’s Hospital, US) sits down with us to discuss the findings from FINEARTS-HF across the ejection fraction spectrum in heart failure with mildly reduced and preserved ejection fraction.Interview Questions:1. What was the reasoning behind this study? What was the study design and patient population?2. What was the study design and patient population?3…
View more
Added:
10 months ago
EuroPCR 25 - Substudy findings from ILUMIEN-IV show that virtual flow reserve was slightly higher after angiography guidance rather than an optical coherence tomography (OCT)-based physiology assessment after percutaneous coronary intervention (PCI) in high-risk angiographic lesions.We are joined by Dr Thomas Johnson (Bristol Heart Institute, Bristol, UK) to discuss findings from a retrospective…
View more
Added:
1 year ago
In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by Dr Alexander Van Rosendael (Leiden University Medical Center, Leiden, NL) to discuss the findings from the CONFIRM2 trial. Conducted from up to 50 international clinical CCTA sites with 35,000 patients, CONFIRM2 aims to improve comprehensive…
View more
Autophagy and Endoplasmic Reticulum Stress in HFpEF
Added:
1 month ago
Review Article
Added:
2 weeks ago
Source:
Interventional Cardiology Review Journal
Long-term follow-up from the FAMOUS-NSTEMI trial suggests that a fractional flow reserve-guided strategy for managing patients with non-ST-segment elevation myocardial infarction (NSTEMI) does not reduce adverse cardiovascular outcomes compared to standard angiography-guided care.¹MethodologyFAMOUS-NSTEMI was a prospective, randomised, controlled trial that enrolled 350 patients with NSTEMI…
View more
Added:
8 months ago
Explore the critical role of comprehensive CT angiography analysis in pre-procedural TAVR planning with Dr Deborah C Nercolini.This presentation, part of the Structural Interventions track, delves into the meticulous anatomical assessment that guides optimal TAVR device selection and implantation strategy. Dr Nercolini addresses the essential measurements and anatomical considerations that…
View more